Mid-day market update: Gold drops over 2%, Leap Therapeutics shares jump

Midway through trading Thursday, the Dow traded down 0.74% to 34,557.75 while the NASDAQ fell 0.67% to 15,060.25. The S&P also fell, dropping 0.79% to 4,445.34.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 41,539,100 cases with around 666,620 deaths. India confirmed a total of at least 33,347,320 cases and 443,920 deaths, while Brazil reported over 21,034,610 COVID-19 cases with 588,590 deaths. In total, there were at least 226,445,290 cases of COVID-19 worldwide with more than 4,661,150 deaths, according to data compiled by Johns Hopkins University.

Leading and Lagging Sectors

Consumer discretionary shares slipped by just 0.1% on Thursday. Meanwhile, top gainers in the sector included Tuesday Morning Corporation TUEM +undefined% (Get Free Alerts for TUEM), up 23% and Vinco Ventures, Inc. BBIG +undefined% (Get Free Alerts for BBIG) up 9%.

In trading on Thursday, materials shares tumbled 1.7%.

Top Headline

US retail sales increased 0.7% in August of 2021, following a revised 1.8% decline in July. Analysts were expecting for a 0.8% decline in retail trade.

Equities Trading UP

Leap Therapeutics, Inc. LPTX +undefined% shares shot up 23% to $2.3650 after the company announced updated data from the first-line cohort of the DisTinGuish Phase 2a trial evaluating DKN-01 combined with BeiGene’s tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer (G/GEJ).

Shares of Tuesday Morning Corporation TUEM +undefined% (Get Free Alerts for TUEM) got a boost, shooting 24% to $2.1450 after a SEC filing showed CEO Fred Hand purchased 511,387 shares of the company's common stock at an average price of $1.76.

TMC the metals company Inc. TMC +undefined% shares were also up, gaining 26% to $12.58 amid increased retail investor interest in the stock on social media.

Equities Trading DOWN

Silverback Therapeutics, Inc. SBTX +24.06% shares tumbled 28% to $11.72. The company presented interim clinical results from a Phase 1/1b clinical study of SBT6050 as a monotherapy and in combination with Merck & Co's Keytruda in patients with advanced or metastatic HER2-expressing or amplified solid tumors.

Shares of Aerie Pharmaceuticals, Inc. AERI +23.79% were down 28% to $11.29 after the company announced topline results of its Phase 2b COMET-1 study evaluating AR-15512 (TRPM8 Agonist) ophthalmic solution for dry eye disease. The company said that the study failed to achieve statistical significance at pre-determined primary endpoints at Day 28.

MacroGenics, Inc. MGNX +26.66% was down, falling 24% to $20.84 as the company disclosed results from Cohort A Part 1 of the Phase 2/3 MAHOGANY clinical trial of margetuximab.


In commodity news, oil traded down 1% to $71.87, while gold traded down 2.3% to $1,752.80.

Silver traded down 4.8% Thursday to $22.65 while copper fell 2.7% to $4.2890.

Euro zone

European shares were higher today. The eurozone’s STOXX 600 gained 0.6%, the Spanish Ibex Index rose 1.18% and the German DAX 30 gained 0.49%. Meanwhile, the London’s FTSE 100 rose 0.31%, French CAC 40 climbed 0.81% and Italy’s FTSE MIB jumped 0.99%.

The Eurozone trade surplus shrank to EUR 20.7 billion in July from EUR 26.8 billion in the year-ago period, while passenger car registrations in the European Union dropped 19.1% year-over-year to 623 thousand units in August. Italy’s trade surplus narrowed to EUR 8.762 billion in July from EUR 9.689 billion in the year-ago month.


US initial jobless claims increased to 332 thousand in the week ending September 11 versus a reading of 312 thousand in the previous week.

The Philadelphia Fed manufacturing index climbed to 30.7 in September from 19.4 in August.

Retail sales increased 0.7% in August of 2021, following a revised 1.8% decline in July.

US business inventories rose 0.5% for July.

US natural-gas supplies surged 83 billion cubic feet last week, the Energy Information Administration said.

The Treasury International Capital report for July will be released at 4:00 p.m. ET.

Benzinga does not provide investment advice. All rights reserved.

Feed news

Latest Forex Analysis

Latest Forex Analysis

Editors’ Picks

EUR/USD stays afloat above 1.1600 as inflation data meet expectations

EUR/USD came under modest bearish pressure in the early European session and continues to have a difficult time regaining its traction. After the data from the euro area revealed that annual CPI stayed unchanged at 3.4% in September, the pair stays relatively calm above 1.1600.


GBP/USD drops below 1.3800 as UK CPIs disappoint

GBP/USD eases below 1.3800, as an unexpected decline in the UK inflation douses the BOE rate hike expectations. Covid resurgence in the UK also undermines the pound. The pair could find support from a broadly subdued US dollar and fresh Brexit optimism. 


Gold: $1791 appears a tough nut to crack for XAU/USD bulls

Gold price is holding the higher ground, extending the previous advance amid a pullback in the US 10-year Treasury yields from five-month highs of 1.672%.

Gold News

Crypto markets prepare for final pullback before next leg up

Bitcoin price is due for a retracement as MRI flashes a sell signal on the daily chart. Ethereum price continues to consolidate under the $3,938 resistance level. Ripple price slides below the $1.09 support level as the crypto markets prepare for a minor correction.

Read more

Tesla: Why it is time to sell TSLA stock

Tesla breaks higher again on Monday as we had called. TSLA to release earnings after the close on Wednesday. Is it time to sell Tesla stock now before earnings?

Read more